摘要
Abstract
Objective To systemically evaluate the efficacy and safety of semaglutide on overweight or obesity without diabetes.Methods Database including PubMed,Embase,Cochrane Library,CNKI,VIP and WanFang were searched.Semaglutide was administered in the treatment group,while placebo or other drug were administered in the control group.The Meta-analysis was performed using RevMan 5.4 software to access the changes of weight,body mass index(BMI),waist circumference,blood pressure,blood glucose,blood lipid and the incidence of adverse reactions.Results A total of 8 researches(4 671 subjects)were eligible.The weight of the treatment group and control group varied respectively at(-13.79±19.49)and(-1.74±18.89)kg,the percents of weight change were(-13.67±17.36)and(-1.04±17.06)％,BMI varied at(-4.99±6.55)and(-0.56±6.64)kg·m-2,waist circumference varied at(-12.11±16.85)and(-3.15±16.46)cm,systolic pressure varied at(-4.97±22.84)and(-0.46±21.83)mmHg,diastolic pressure varied at(-2.58±15.69)and(-0.50±15.14)mmHg,the fasting blood glucose varied at(-7.37±22.34)and(0.87±21.57)mg·mL,total cholesterol changed by(-0.96±25.30)％and(4.38±25.88)％,low-density lipoprotein cholesterol changed by(-3.28±38.48)％and(2.67±38.71)％,VLDL-C changed by(-15.94±59.35)％and(2.65±67.55)％,triglyceride changed by(-15.96±59.30)％and(2.49±67.15)％,and the above differences between two groups were significant(P＜0.01).The adverse reaction incidences of the treatment group and control group were 89.02％and 85.56％respectively with significant difference(P＜0.05).Conclusion In treatment of overweight or obesity without diabetes,semaglutide is proved to have obvious efficacy and can also improve blood pressure,blood glucose and lipid.The gastrointestinal reaction incidence is relatively high.关键词
司美格鲁肽/超重/肥胖/非糖尿病人群/临床疗效/安全性评价Key words
semaglutide/overweight/obesity/non diabetes/clinical efficacy/safety evaluation分类
医药卫生
